Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its previously projected $1.6  billion to $2  billion forecast but well ‍below ...

Moderna Inc.’s chairman says the Trump administration’s vaccine policy changes are part of a broader attack on science that may have only just begun.

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to cancer and rare disease mRNA programs.

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. The latest sign of that was Moderna’s presentation here at the European ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the decline of its COVID vaccine business. Moderna lowered the high end of its ...

Moderna shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its cost-cutting measures are helping offset the decline of its COVID business. The ...